Publications

1. Meermeier EW, Bergsagel PL, Chesi M. Next-Generation Therapies for Multiple Myeloma. Annu Rev Cancer Biol. 2024 Jun; 8:351-371 Epub 2024 Jan 11
   View PubMed
2. Maura F, Coffey DG, Stein CK, Braggio E, Ziccheddu B, Sharik ME, Du MT, Tafoya Alvarado Y, Shi CX, Zhu YX, Meermeier EW, Morgan GJ, Landgren O, Bergsagel PL, Chesi M. The genomic landscape of Vk*MYC myeloma highlights shared pathways of transformation between mice and humans. Nat Commun. 2024 May 7; 15 (1):3844 Epub 2024 May 07
   View PubMed
3. Welsh SJ, Barwick BG, Meermeier EW, Riggs DL, Shi CX, Zhu YX, Sharik ME, Du MT, Abrego Rocha LD, Garbitt VM, Stein CK, Petit JL, Meurice N, Tafoya Alvarado Y, Fonseca R, Todd KT, Brown S, Hammond ZJ, Cuc NH, Wittenberg C, Herzog C, Roschke AV, Demchenko YN, Chen WD, Li P, Liao W, Leonard WJ, Lonial S, Bahlis NJ, Neri P, Boise LH, Chesi M, Bergsagel PL. Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma. Blood Cancer Discov. 2024 Jan 8; 5 (1):34-55
   View PubMed
4. Meermeier EW, Bergsagel PL. Revisiting checkpoint inhibitors for myeloma: maintenance after stem cell transplant. J Clin Invest. 2023 Feb 15; 133 (4)
   View PubMed
5. Meermeier EW, Zheng CL, Tran JG, Soma S, Worley AH, Weiss DI, Modlin RL, Swarbrick G, Karamooz E, Khuzwayo S, Wong EB, Gold MC, Lewinsohn DM. Human lung-resident mucosal-associated invariant T cells are abundant, express antimicrobial proteins, and are cytokine responsive. Commun Biol. 2022 Sep 9; 5 (1):942 Epub 2022 Sept 09
   View PubMed
6. Meermeier EW, Welsh SJ, Sharik ME, Du MT, Garbitt VM, Riggs DL, Shi CX, Stein CK, Bergsagel M, Chau B, Wheeler ML, Bezman N, Wang F, Strop P, Bergsagel PL, Chesi M. Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. Blood Cancer Discov. 2021 Jul; 2(4):354-369.
   View PubMed
7. Khuzwayo S, Mthembu M, Meermeier EW, Prakadan SM, Kazer SW, Bassett T, Nyamande K, Khan DF, Maharaj P, Mitha M, Suleman M, Mhlane Z, Ramjit D, Karim F, Shalek AK, Lewinsohn DM, Ndung'u T, Wong EB. MR1-Restricted MAIT Cells From The Human Lung Mucosal Surface Have Distinct Phenotypic, Functional, and Transcriptomic Features That Are Preserved in HIV Infection. Front Immunol. 2021; 12:631410 Epub 2021 Apr 09
   View PubMed
8. Awad W, Meermeier EW, Sandoval-Romero ML, Le Nours J, Worley AH, Null MD, Liu L, McCluskey J, Fairlie DP, Lewinsohn DM, Rossjohn J. Atypical TRAV1-2(-) T cell receptor recognition of the antigen-presenting molecule MR1. J Biol Chem. 2020 Oct 16; 295 (42):14445-14457 Epub 2020 Aug 14
   View PubMed
9. Narayanan GA, McLaren JE, Meermeier EW, Ladell K, Swarbrick GM, Price DA, Tran JG, Worley AH, Vogt T, Wong EB, Lewinsohn DM. The MAIT TCRbeta chain contributes to discrimination of microbial ligand. Immunol Cell Biol. 2020 Oct; 98 (9):770-781 Epub 2020 July 12
   View PubMed
10. Narayanan GA, Nellore A, Tran J, Worley AH, Meermeier EW, Karamooz E, Huber ME, Kurapova R, Tafesse FG, Harriff MJ, Lewinsohn DM. Alternative splicing of MR1 regulates antigen presentation to MAIT cells. Sci Rep. 2020 Sep 22; 10 (1):15429 Epub 2020 Sept 22
    View PubMed
11. Chesi M, Stein CK, Garbitt VM, Sharik ME, Asmann YW, Bergsagel M, Riggs DL, Welsh SJ, Meermeier EW, Kumar SK, Braggio E, Bergsagel PL. Monosomic loss of MIR15A/MIR16-1 is a driver of multiple myeloma proliferation and disease progression. Blood Cancer Discov. 2020 Jul; 1 (1):68-81
    View PubMed
12. de Campos CB, Zhu YX, Sepetov N, Romanov S, Bruins LA, Shi CX, Stein CK, Petit JL, Polito AN, Sharik ME, Meermeier EW, Ahmann GJ, Armenta IDL, Kruse J, Bergsagel PL, Chesi M, Meurice N, Braggio E, Stewart AK. Identification of PIKfyve kinase as a target in multiple myeloma. Haematologica. 2020 Jun; 105(6):1641-1649. Epub 2019 Oct 03.
    View PubMed
13. Cansler M, Null M, Meermeier E, Swarbrick G, Lewinsohn D, Harriff M. Generation of MR1-Restricted T Cell Clones by Limiting Dilution Cloning of MR1 Tetramer(+) Cells. Methods Mol Biol. 2020; 2098:219-235
    View PubMed
14. Suliman S, Murphy M, Musvosvi M, Gela A, Meermeier EW, Geldenhuys H, Hopley C, Toefy A, Bilek N, Veldsman A, Hanekom WA, Johnson JL, Boom WH, Obermoser G, Huang H, Hatherill M, Lewinsohn DM, Nemes E, Scriba TJ. MR1-Independent Activation of Human Mucosal-Associated Invariant T Cells by Mycobacteria. J Immunol. 2019 Dec 1; 203 (11):2917-2927 Epub 2019 Oct 14
    View PubMed
15. Wong EB, Gold MC, Meermeier EW, Xulu BZ, Khuzwayo S, Sullivan ZA, Mahyari E, Rogers Z, Kloverpris H, Sharma PK, Worley AH, Lalloo U, Baijnath P, Ambaram A, Naidoo L, Suleman M, Madansein R, McLaren JE, Ladell K, Miners KL, Price DA, Behar SM, Nielsen M, Kasprowicz VO, Leslie A, Bishai WR, Ndung'u T, Lewinsohn DM. TRAV1-2(+) CD8(+) T-cells including oligoconal expansions of MAIT cells are enriched in the airways in human tuberculosis. Commun Biol. 2019; 2:203 Epub 2019 June 05
    View PubMed
16. Drain PK, Bajema KL, Dowdy D, Dheda K, Naidoo K, Schumacher SG, Ma S, Meermeier E, Lewinsohn DM, Sherman DR. Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection. Clin Microbiol Rev. 2018 Oct; 31 (4) Epub 2018 July 18
    View PubMed
17. Harriff MJ, McMurtrey C, Froyd CA, Jin H, Cansler M, Null M, Worley A, Meermeier EW, Swarbrick G, Nilsen A, Lewinsohn DA, Hildebrand W, Adams EJ, Lewinsohn DM. MR1 displays the microbial metabolome driving selective MR1-restricted T cell receptor usage. Sci Immunol. 2018 Jul 13; 3 (25)
    View PubMed
18. Meermeier EW, Harriff MJ, Karamooz E, Lewinsohn DM. MAIT cells and microbial immunity. Immunol Cell Biol. 2018 Jul; 96 (6):607-617 Epub 2018 Mar 09
    View PubMed
19. Nemes E, Meermeier EW, Scriba TJ, Walzl G, Malherbe ST, Lewinsohn DM. Diagnostic Challenge of Tuberculosis Heterogeneity. Semin Respir Crit Care Med. 2018 Jun; 39 (3):286-296 Epub 2018 Aug 02
    View PubMed
20. Meermeier EW, Lewinsohn DM. Early clearance versus control: what is the meaning of a negative tuberculin skin test or interferon-gamma release assay following exposure to Mycobacterium tuberculosis? F1000Res. 2018; 7 Epub 2018 May 25
    View PubMed
21. Meermeier EW, Laugel BF, Sewell AK, Corbett AJ, Rossjohn J, McCluskey J, Harriff MJ, Franks T, Gold MC, Lewinsohn DM. Human TRAV1-2-negative MR1-restricted T cells detect S. pyogenes and alternatives to MAIT riboflavin-based antigens. Nat Commun. 2016 Aug 16; 7:12506
    View PubMed
22. Laugel B, Lloyd A, Meermeier EW, Crowther MD, Connor TR, Dolton G, Miles JJ, Burrows SR, Gold MC, Lewinsohn DM, Sewell AK. Engineering of Isogenic Cells Deficient for MR1 with a CRISPR/Cas9 Lentiviral System: Tools To Study Microbial Antigen Processing and Presentation to Human MR1-Restricted T Cells. J Immunol. 2016 Aug 1; 197 (3):971-82 Epub 2016 June 15
    View PubMed
23. Stickles AM, Ting LM, Morrisey JM, Li Y, Mather MW, Meermeier E, Pershing AM, Forquer IP, Miley GP, Pou S, Winter RW, Hinrichs DJ, Kelly JX, Kim K, Vaidya AB, Riscoe MK, Nilsen A. Inhibition of cytochrome bc1 as a strategy for single-dose, multi-stage antimalarial therapy. Am J Trop Med Hyg. 2015 Jun; 92 (6):1195-201 Epub 2015 Apr 27
    View PubMed
24. Alzhanova D, Hammarlund E, Reed J, Meermeier E, Rawlings S, Ray CA, Edwards DM, Bimber B, Legasse A, Planer S, Sprague J, Axthelm MK, Pickup DJ, Lewinsohn DM, Gold MC, Wong SW, Sacha JB, Slifka MK, Fruh K. T cell inactivation by poxviral B22 family proteins increases viral virulence. PLoS Pathog. 2014 May; 10 (5):e1004123 Epub 2014 May 15
    View PubMed
25. Pou S, Winter RW, Nilsen A, Kelly JX, Li Y, Doggett JS, Riscoe EW, Wegmann KW, Hinrichs DJ, Riscoe MK. Sontochin as a guide to the development of drugs against chloroquine-resistant malaria. Antimicrob Agents Chemother. 2012 Jul; 56 (7):3475-80 Epub 2012 Apr 16
    View PubMed
26. Dreher TW, Brown N, Bozarth CS, Schwartz AD, Riscoe E, Thrash C, Bennett SE, Tzeng SC, Maier CS. A freshwater cyanophage whose genome indicates close relationships to photosynthetic marine cyanomyophages. Environ Microbiol. 2011 Jul; 13 (7):1858-74 Epub 2011 May 23
    View PubMed